Novo Nordisk and Neose announce initiation of phase 1 clinical trial of long-acting factor VIIa

Novo Nordisk A/S and Neose Technologies, Inc. today announced that Novo Nordisk has initiated a phase 1 clinical trial of GlycoPEGylated factor VIIa, a long-acting version of NovoSeven® Coagulation Factor VIIa

COPENHAGEN, Denmark and HORSHAM, PA, USA | June 15, 2007 |
Novo Nordisk A/S (NYSE: NVO) and Neose Technologies, Inc. (NasdaqGM: NTEC) today announced that Novo Nordisk has initiated a phase 1 clinical trial of GlycoPEGylated factor VIIa, a long-acting version of NovoSeven® Coagulation Factor VIIa (recombinant). The trial will assess the safety and pharmacokinetics of GlycoPEGylated factor VIIa in healthy volunteers.

GlycoPEGylated factor VIIa is being developed by Novo Nordisk under a licence agreement with Neose. The initiation of the phase I study triggers an undisclosed milestone payment to Neose under the licence agreement.

“Novo Nordisk is committed to developing therapies to prevent or reduce bleeding episodes and to improve the quality of life in patients with haemophilia. We are pleased that our collaboration with Neose has resulted in a long-acting factor VIIa clinical development candidate that has the potential to contribute to this goal,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

"We are pleased that GlycoPEGylated factor VIIa has entered clinical development, making it the third GlycoPEGylated therapeutic protein to reach this milestone. Novo Nordisk has proved to be an ideal partner for this development candidate, and we are confident that their clinical expertise will continue to add value to this programme," said George J Vergis, PhD, Neose president and chief executive officer.

About coagulation factor VII
Factor VII/VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX. The worldwide market for recombinant factor VII was approximately 1 billion US dollars in 2006, with Novo Nordisk being the only participant.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of 15 billion US dollars. For more information, please visit www.neose.com.

SOURCE: Novo Nordisk A/S

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top